Suppr超能文献

多发性硬化症中的继发性发作性运动障碍:临床-影像学特征和治疗。七例患者的病例报告。

Secondary paroxysmal dyskinesia in multiple sclerosis: Clinical-radiological features and treatment. Case report of seven patients.

机构信息

Department of Neurology, Pontificia Universidad Católica de Chile, Hospital Sótero del Río, Santiago, Chile.

Department of Neurology, Pontificia Universidad Católica de Chile, Santiago, Chile.

出版信息

Mult Scler. 2017 Nov;23(13):1791-1795. doi: 10.1177/1352458517702968. Epub 2017 Apr 11.

Abstract

Secondary paroxysmal dyskinesias (SPDs) are short, episodic, and recurrent movement disorders, classically related to multiple sclerosis (MS). Carbamazepine is effective, but with risk of adverse reactions. We identified 7 patients with SPD among 457 MS patients (1.53%). SPD occurred in face ( n = 1), leg ( n = 2), or arm +leg ( n = 4) several times during the day. Magnetic resonance imaging (MRI) showed new or enhancing lesions in thalamus ( n = 1), mesencephalic tegmentum ( n = 1), and cerebellar peduncles ( n = 5). Patients were treated with clonazepam and then acetazolamide ( n = 1), acetazolamide ( n = 5), or levetiracetam ( n = 1) with response within hours (acetazolamide) to days (levetiracetam). No recurrences or adverse events were reported after a median follow-up of 33 months.

摘要

继发性发作性运动障碍(SPD)是一种短暂、间歇性和复发性运动障碍,通常与多发性硬化症(MS)有关。卡马西平有效,但有不良反应的风险。我们在 457 名 MS 患者中发现了 7 名 SPD 患者(1.53%)。SPD 在一天中多次发生在面部(n=1)、腿部(n=2)或手臂+腿部(n=4)。磁共振成像(MRI)显示丘脑(n=1)、中脑被盖(n=1)和小脑脚(n=5)有新的或强化病变。患者接受氯硝西泮治疗,然后接受乙酰唑胺(n=1)、乙酰唑胺(n=5)或左乙拉西坦(n=1)治疗,数小时(乙酰唑胺)至数天(左乙拉西坦)内有反应。在中位随访 33 个月后,没有复发或不良反应报告。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验